Positive Relationship between CD133 Expression and Clinicopathologic Factors in Colorectal Cancer by YOSHIDA Tomohiko et al.
Showa Univ J Med Sci 22（1）, 9～18, March 2010
Positive Relationship between CD133 Expression and  
Clinicopathologic Factors in Colorectal Cancer
Tomohiko YOSHIDA, Toshiaki KUNIMURA, Tomoaki MORI,  
Shuuei ARIMA, Takahiro YAMAZAKI, Yuuko DATE,  
Mutuko OMATSU, Tomoko SUGIYAMA, Kouji SAITOU,  
Naoji HOSAKA and Toshio MOROHOSHI
Abstract : The expression of the CD133 cancer stem cell marker correlates 
with metastasis and prognosis for many cancers, but no correlation has been 
established in colorectal cancer.  We used immunohistochemical analysis to 
examine the relationship between CD133 expression and clinical malignancy 
factors such as lymph node metastasis and hepatic metastasis in colorectal 
cancer.  The subjects of this study were 104 patients with colorectal cancer 
who were examined in our hospital and treated by surgical excision of the 
tumor between 2004 and 2007.  Representative tissue sections were immu-
nohistochemically stained using an anti-CD133 antibody.  Patients showing 
staining of 50％ or more of the tumor gland duct were classified into the 
CD133-positive group, which consisted of 36 patients.  Those staining less 
than 50％ of the tumor gland duct were classified into the CD133-negative 
group, which consisted of 68 patients.  Patients with lymph node metastasis 
accounted for 63.9％ of the positive group（23 / 36 patients）and 33.8％ of 
the negative group（23 / 68 patients）, and the difference was signicant（P＝
0.00331）.  Patients with hepatic metastasis accounted for 27.8％ of the positive 
group（10 / 36 patients）and 10.3％ of the negative group（7 / 68 patients）, 
and the difference was signicant（P＝0.0218）.  Classication of these patients 
according to cancer stage determined on the basis of the International Union 
Against Cancer（UICC）stage showed that ve patients were in stage I, one 
patient in stage II, 20 patients in stage III, and 10 patients in stage IV in 
the positive group ; and 20 patients were in stage I, 22 patients in stage II, 
18 patients in stage III, and eight patients in stage IV in the negative group. 
There was a signicant difference in the numbers of patients in each group（P
＝0.000127）.  Differences in the number of patients with lymphovascular inva-
sion and those with venous invasion were also signicant between the groups
（P＝0.0248 and P＝0.0292, respectively）.  No significant differences were 
observed for any other factors.  These ndings indicate that the CD133-positive 
group has a higher risk of metastasis.
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Introduction
　A hierarchical model has been proposed recently in which a small population of cancer 
stem cells with self-renewal capability and multipotency have tumorigenic potential1-3）.  The 
existence of cancer stem cells was rst demonstrated by the transplantation of human acute 
myeloid leukemia cells into severe combined immunodecient（SCID）mice4）.  The existence 
of cancer stem cells has since been established by their separation from other cell types and 
identication and the analysis of their properties5-9）.  The current denition of cancer stem 
cells includes the following characteristics : 1）tumorigenicity, 2）the ability to form a cell 
group with low or no tumorigenicity, and 3）self-renewal capability 10）.
　CD133 is a ve-transmembrane protein with a molecular mass of 117 kDa that is selec-
tively localized in the cell membrane protrusions in hematopoietic and neural stem cells 11）. 
The expression of CD133 in cancer stem cells has been demonstrated using transplantation 
experiments in mice8, 12）.  CD133 is expressed in cancer stem cells in various solid cancers 
such as brain tumor 8, 12, 13）, prostate cancer 14）, kidney cancer 15）, melanoma16, 17）, ovarian can-
cer 18）, hepatocellular cancer19-21）, lung cancer22）, and colorectal cancer23-25）.  The relationship 
between CD133 expression and clinicopathologic ndings in colorectal cancer has not been 
fully studied and no functional basis for its expression in these cells has been established.
　In an investigation of colorectal cancer, we assessed the relationship between CD133 
expression and clinicopathologic ndings such as lymph node metastasis and hepatic metasta-
sis.
Materials and Methods
Patients and specimens
　We enrolled 144 patients with colorectal cancer in this study.  These patients had under-
gone surgical excision at Showa University Hospital or Showa University Toyosu Hospital 
between 2004 and 2007.  Patients with multiple cancers, or multiple primary cancers, or 
those given adjuvant therapy, were excluded from the study.  Previously, Kojima et al used 
immunohistochemical analysis to show that there was no CD133 expression in 29 patients 
with poorly differentiated adenocarcinoma 26）.  Therefore, patients with poorly differentiated 
adenocarcinoma were excluded from our study.  Patients with lymph node metastasis and 
those with hepatic metastasis were diagnosed histologically.  Excised tissue samples from 
patients meeting the selection criteria were xed in 10％ formalin and the tumor diameter 
and gross appearance were recorded.  All of the tissue specimens were excised in accor-
dance with the general rules of the Japanese Society for Cancer of the Colon and Rectum. 
After representative sections were embedded in parafn, thin sections were prepared and 
stained with hematoxylin-eosin（HE）for histological evaluation of venous invasion by tumor 
cells.
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Immunohistochemical staining
　Immunohistochemical staining of representative colorectal cancer tissue sections for CD133 
was performed using an anti-CD133 primary antibody（Miltenyi Biotec Inc., Auburn, CA, 
USA）.  Thin slices were heat-treated with ethylenediaminetetraacetic acid（EDTA）for 
90 min after deparaffinization and hydrophilic treatment.  Endogenous peroxidase activity 
was inhibited using 0.3％ hydrogen peroxide solution.  The primary anti-CD133 antibody 
was used at a dilution of 1 : 5 and reacted with the tissue antigen for 32 min.  A second-
ary antibody was raised against biotinylated immunoglobulin and was labeled with avidin 
horseradish peroxidase（HRP）.  CD133 staining was visualized using a Ventana I-View DAB 
universal kit（Roche, Tokyo, Japan.  The reaction was enhanced using copper sulfate.  After 
nuclear staining with hematoxylin, the slices were mounted on slides.
Evaluation of CD133 immunopositivity
　CD133 immunopositivity was evaluated using the assay method reported by Horst et al 27） 
Five medium power elds（×200）per section were viewed.
　Patients showing staining of ＜50％ of the tumor gland duct were classified into the 
negative group, and those showing staining of ≥50％ were classified into the positive 
group.  Positive CD133 staining of the tumor gland duct was established by staining of the 
membrane surface of the ductal lumen or of debris in the tumor gland duct.  Statistical 
analyses were carried out using the M×N χ2 test and Welch’s t-test with P＜0.05 indicating 
a signicant difference.
Results
Clinicopathologic ndings
　The clinicopathologic ndings for the 104 selected patients are shown in Table 1.  The 
patients consisted of 71 males and 33 females with a mean age of 69.2±11.6 yr.  The mean 
size of all the tumors was 45.4±19.6 mm.  The tumor onset sites were in the cecum in 
four patients, ascending colon in 18 patients, transverse colon in 12 patients, descending 
colon in 14 patients, sigmoid colon in 32 patients, and rectum in 24 patients.  Thirty-nine 
patients had well-differentiated adenocarcinoma and 65 patients had moderately differentiated 
adenocarcinoma（Figs. 1A and 1B）.  Lymph node metastasis was observed in 58 patients
（Fig. 2A）and hepatic metastasis was observed in 17 patients（Fig. 2B）.  There were 11 T1 
patients, 20 T2 patients, 61 T3 patients, and 12 T4 patients as determined in accordance with 
tumor node metastasis（TNM）classication.  Using the UICC classication, 25 patients were 
identied to be in stage I, 23 patients in stage II, 38 patients in stage III, and 18 patients 
in stage IV.  Lymphovascular invasion was observed in 79 patients and venous invasion was 
observed in 76 patients.
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Table 1. Relationship between CD133 expression and clinicopathologic fac-
tors in colorectal cancer
Cd133 expression
Total low High p value
n 104 68 36
Age（years）
Mean±S.D 69.2±11.6 67.5±12.7 70.6±9.75 0.211
Gender
Male 71 43 28
Female 33 25 8 0.131
Tumor size（mm） 45.4±19.6 45.2±19.0 45.7±21.0 0.912
Location
Cecum 4 2 2
Ascending 18 14 4
Trans 12 10 2
D / C 14 8 6
S / C 32 16 16
Rectum 24 18 6 0.151
Histology
well 39 28 11
moderately 65 40 25 0.287
Depth of tumor
pT1 11 10 1
pT2 20 11 9
pT3 61 41 20
pT4 12 6 6 0.141
lymphnode metastasis
negative 58 45 13
positive 46 23 23 0.00331
Liver metastasis
Negative 87 61 26
Positive 17 7 10 0.0218
UICC Stage
Ⅰ 25 20 5
Ⅱ 23 22 1
Ⅲ 38 18 20
Ⅳ 18 8 10 0.000127
lymphatic invasion
Negative 25 21 4
Positive 79 47 32 0.0248
Venous invasion
Negative 28 23 5
Positive 76 45 31 0.0292
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Assessment of correlation between CD133 expression and clinicopathological ndings
　There were 36 patients in the positive group and 68 patients in the negative group（Figs. 
3A and 3B）.  Their mean ages were 70.6±9.75 yr for the positive group and 67.5±12.7 yr 
for the negative group, which is not a signicant difference（P＝0.211）.  The positive group 
consisted of 28 males and eight females, whereas the negative group consisted of 43 males 
A : Well-differentiated adenocarcinoma
A
A
B
B
B : Moderately differentiated adenocarcinoma
Fig. 1.　Tissue image（HE）
A : Patient with lymph node metastasis B : Patient with hepatic metastasis
Fig. 2.　Tissue image（HE）
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and 25 females and there was no signicant difference in the gender ratio between the two 
groups.  The tumor diameters were 45.7±21.0 mm for the positive group and 45.2±19.0 mm 
for the negative group, which were not signicantly different（P＝0.912）.  The tumor onset 
sites were identied to be the cecum in two patients, ascending colon in four patients, trans-
verse colon in two patients, descending colon in six patients, sigmoid colon in 16 patients, 
and rectum in six patients in the positive group.  In the negative group, the tumor onset 
sites were in the cecum in two patients, ascending colon in 14 patients, transverse colon in 
10 patients, descending colon in eight patients, sigmoid colon in 16 patients, and rectum in 
18 patients.  There was no signicant difference in tumor onset site between the two groups
（P＝0.151）.  Analysis of the histological type of colorectal adenocarcinoma revealed that 11 
patients had well-differentiated adenocarcinoma and 25 patients had moderately differenti-
ated adenocarcinoma in the positive group.  In the negative group, 28 patients had well-
differentiated adenocarcinoma and 40 patients had moderately differentiated adenocarcinoma. 
There was no signicant difference in histological type between the two groups（P＝0.287）. 
Patient distribution according to T classication identied one T1 patient, nine T2 patients, 
20 T3 patients, and six T4 patients in the positive group.  In the negative group there were 
10 T1 patients, 11 T2 patients, 41 T3 patients, and six T4 patients.  No signicant difference 
in this distribution was observed between the two groups（P＝0.1408）.  Lymph node metas-
A :  Patients with a CD133 positivity rate 
of ＜50％ of the tumor gland duct 
were classied into the negative group.
B :  Patients with a CD133 positivity rate 
of ≥50％ of the tumor gland duct 
were classied into the positive group.
Fig. 3.　Immunohistochemical evaluation of CD133 in colorectal cancer
The presence of CD133-positive cells in the tumor gland duct was determined on 
the basis of the staining of the membrane surface of the ductal lumen or staining 
of debris in the tumor gland duct.
A B
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tasis was observed in 63.9％（23 / 36 patients）of the positive group and in 33.8％（23 / 68 
patients）of the negative group.  The difference was signicant between the two groups（P
＝0.00331）.  Hepatic metastasis was observed in 27.8％（10 / 36 patients）of the positive 
group and 10.3％（7 / 68 patients）of the negative group, and the difference is signicant（P
＝0.0218）.  Patient distribution according to the UICC stage classication showed that ve 
patients were in stage I, one patient in stage II, 20 patients in stage III, and 10 patients in 
stage IV in the positive group, whereas 20 patients were in stage I, 22 patients in stage II, 
18 patients in stage III, and eight patients in stage IV in the negative group.  A signicant 
difference in patient distribution was observed between the two groups（P＝0.000127）. 
Lymphovascular invasion was observed in 88.9％（32 / 36 patients）of the positive group and 
69.1％（47 / 68 patients）of the negative group, and the difference was signicant（P＝0.0248）. 
Venous invasion was observed in 86.1％（31 / 36 patients）of the positive group and 66.2％
（45 / 68 patients）of the negative group, and the difference was signicant（P＝0.0292）.
Discussion
　A number of recent studies of colorectal cancer cells from CD133-positive patients 
have shown that the cells have different characteristics than those from CD133-negative 
patients.  O’Brien et al isolated CD133-positive cells from surgically excised colorectal cancer 
specimens, transplanted them into SCID mice and found that they had more than 200-
fold higher tumorigenicity than CD133-negative cells 23）.  In addition, Ricci-Vitiani et al using 
subcutaneously transplanted clinical samples of colorectal cancer, found that CD133-positive 
cell populations formed tumors similar to the original tumors24）.  This also established that 
the passage of CD133-positive cells is possible 24）.  The CD133-positive cell population in 
colorectal cancer cell lines has higher tumorigenicity with greater colony formation, invasion 
and growth in nude mice than CD133-negative cells 25）.
　Two previous studies of the clinicopathology of CD133-positive colorectal cancer tumors 
have also shown no signicant relationship between CD133 expression and tumor diameter 
or tumor depth determined on the basis of T classication 26, 27）.  Kojima et al demonstrated 
the uniformity of cancer stem cell distribution in tumors and observed no relationship 
between CD133 expression and tumor diameter or tumor depth26）.  These ndings do not 
necessarily reect the previously mentioned data using a colorectal cancer cell line.
　In contrast to our findings, Kojima et al found no significant relationship between the 
presence of CD133-positive cells and lymph node metastasis, lymphovascular invasion or 
venous invasion 26）.  Their interpretation may result from their analysis of the CD133 immu-
nohistochemical data in which they used a cutoff for a positive signal of 10％ for the entire 
tumor, whereas we set the cutoff at 50％.  Therefore, their interpretation failed to identify 
a relationship between CD133-positive cells and vascular invasion and subsequent metastatic 
invasion.  In the present study, we established that there is a signicant relationship between 
the presence of CD133-positive cells and each of the clinicopathologic factors associated 
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with colorectal cancer.  It has been established that CD133-positive cells are associated with 
lymphovascular invasion and lymph node metastasis in pancreatic cancer 28）.  It has been 
proposed that the microenvironment of cancer stem cells is critical to their maintenance 
and self-renewal because of the close interactions between cancer stem cells and endothelial 
cells 29）.  The results of the present study indicate that the microenvironment of cancer stem 
cells is favorable for lymph node and venous invasions, thereby leading to lymph node and 
hepatic metastases28）.  Although the specic prognosis of patients with colorectal cancer was 
not assessed, a review of the literature showed a signicantly lower 5-year survival rate for 
CD133-positive patients, probably as a result of higher rates of lymphatic and hematogenous 
metastases 26, 27）.
　Here, we have reported on the signicant relationship between the presence of CD133-
positive cells and metastases of the lymph node and liver including vascular invasion.  Not 
all CD133-positive cells have characteristics similar to cancer stem cells.  O’Brien et al 
reported that only 1 / 262 of CD133-positive cells actually showed characteristics similar to 
those of cancer stem cells 23）.
　An additional cancer stem cell marker that is important in colorectal cancer is CD44. 
CD44 positivity group has characteristics of the cancer stem cell even if it is single ; further 
it has been reported that EpCAM-positive / CD44-positive / CD166-positive cell population 
more strongly show those characteristics 30）.
　Therefore, it is possible that CD133-negative / CD44-positive cell populations more effi-
ciently identify cancer stem cells31）.  A systematic investigation using immunohistochemical 
analyses will be required to accurately identify markers strongly associated with the cancer 
stem cell population.
Conclusions
　The presence of CD133-positive cancer stem cells is signicantly related to the risk of 
vascular invasion and lymph node and hepatic metastases in colorectal cancer patients. 
CD133-positive cancer stem cells can be a malignancy indicator for colorectal cancer as in 
other cancers.
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